ArticleArchives of microbiology2026
Characterization of a monoclonal antibody recognizing a conserved linear neutralizing epitope of pseudorabies virus gB protein.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Pseudorabies virus (PRV), an α-herpesvirus, infects a variety of mammals. It is mainly prevalent in domestic pigs but can also infect humans, posing significant public health risks. The glycoprotein B (gB), a crucial structural protein involved in viral entry and immune recognition, is a key target for neutralizing antibodies of PRV. This study expressed gB glycoprotein to immunise mice using eukaryotic and prokaryotic systems. The hybridoma cell line secreting anti-gB antibodies was analysed, and the neutralising epitope targeted by this monoclonal antibody was identified. Six anti-PRV monoclonal antibodies were generated via the cell fusion technique. The characterization of mAbs revealed that 4A10 exhibited an IFA titer of 1:3200 and neutralization titer of 1:2
Indexed as
Identifiers
42726283What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.